Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy

Next Previous
X
Search
Trial Profile

Phase 2 Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen Oral Immunotherapy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 101 (Primary)
  • Indications Peanut hypersensitivity
  • Focus Registrational; Therapeutic Use
  • Acronyms ARC001
  • Sponsors Aimmune Therapeutics; Allergen Research Corporation

    • Most Recent Events

    • 31 Jan 2020 According to an Aimmune Therapeutics media release, in connection with the FDA approval announcement the company will host a conference call and webcast today.
    • 31 Jan 2020 According to an Aimmune Therapeutics media release, the the U.S. Food and Drug Administration (FDA) approved PALFORZIA(AR-101) for treatment of peanut allergy in children and adolescents aged 4 - 17 years. The Biologics License Application (BLA) included efficacy and safety data from seven clinical studies, including the pivotal Phase 3 PALISADE and RAMSES clinical trials. In addition, data from ARC001, ARC002, ARC004, ARC008 and ARC011 were included.
    • 31 Oct 2017 According to an Aimmune therapeutics media release, results from this trial have been published in The Journal of Allergy and Clinical Immunology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top